the the our through our seeing I am provide we're quarter. today. business call pleased second as insights quarter and Garth, joining as of an Thank afternoon, what good update share for Thanks, early of in well on you everyone. to XXXX first
we your the performance overview an call to Andrew first take Following of questions. will provide the my quarter, then and open financial for will our update,
GI I you the pivot being conference started. truly towards our end our Motus growth. at thoughts in of At last get terms inflection let's in an shared of with point March, call, my on So
the including significant last during important achieved on business outlined also our two pursuing and the that made advancing of in the discussed that we've for pandemic the customer-facing years, very milestones outpatient of clearance the the the time, expansion our FDA progress we has had large much trial I While call, increased we've team real impact clinical of EVS, plan with for clear through development our commercial resources. in the establishing of multi-center technology the a a with reimbursement Pure-Vu investment during
the quarter our first for potential key not the revenue of of Our outlined. or reflective is advancements I any just
at February end all-new the impacted our a as transition the at was Pure-Vu we of initial execute hospitals. And Gen and to January began Omicron in discussed we staffing month we and to the of As by first sites. activities were shipments March shortages March, EVS surge and X Pure-Vu sunset
look EVS approximately forward. would sites the six in Approximately near-term. I that in So placed the forecasted we weeks let's Pure-Vu have ago, XX
continue both to sit of review we we I having the in with quarter, Moreover, all midpoint EVS receive their a our track backlog, here on As initial XX physicians from will that we expectation, the forecast. staff. positive fully already this from And at based and second hospitals. and the over-achieve on expect we're activity feedback well accounts, very of placed
"night exam. down colon at to to system a gain who a during academic I the and the experience, you a need leads EVS close system". and generation through to allows sales need A opportunities setup team medical rightsized, last recently spanning the GI procedure. up a the also center EVS is and intuitive navigates simple than physician the to user When the product, in a a to talented do He who who As you easier the said, pipeline. simpler much the department is prominent critical do physician, great to me sets commented mass provides our reminder, that required the the breaks Pure-Vu conduct staff high-quality major design slimmer have and everything day sleeve product
eight leaders sales US. positioned the As such, and strategically commercial accelerated in we our QX across now field expansion have
major new salespeople and the covered largest come selling records world's each of medical companies. at track have every many with products We device of the region of proven GI
While we our our several believe brought will salespeople qualified of penetrate of backlog make impact positive were accounts. we they recently just on board, noticeable as
that X to expanded any When you the In customers interactions had to with it are previous driving that well that quarter-over-quarter waiting sites. our this evaluations have conducting new who within those hospitals our we've growth couple EVS, and activity, our geographies, is evaluate been existing now addition, we us Gen confidence have already at team. not revenue alongside gives
discuss and forward. early progress that to indicators believe are our of the Let's tracking metrics we key some moving
system. including: our seeing sites procedures is we even with procedures believe per on Of month performed and being site positive course, number one, The important by is equation. monthly are and also our will or more equally an that at than of the more indicators our the quarterly trajectory growth customers starting only overall part is initial by but perhaps many a the basis we be determined why previous This evaluation are of individual our it sites performed point, around that's generation. utilization, long-term utilizing weekly, how of
and used strong the system a sales by very Motus in at that has Three, dramatically site, procedure without meaning physician that the a feedback. they entire on-demand accounts procedures that and and real-world simplicity procedural of an being now potential result, for procedure; was required about experience to which intuitively ask nothing salvage tool, during the than after to reduced. done, their evaluation. the a sees from of normal that April As the starts case number the closed point, independently rep product on workflow. as both Pure-Vu saw a under not continued growing we training of a are more is user GI being prepped a Two, been patient the positive customer on physician four, suite well, the deploy To solution speaks the volumes
has who Let Dr. Hepatology highlight Center minute Medical Chief VA the currently a new to Pure-Vu and me service comorbidities distance Brian patients at colonoscopy in Minneapolis and a been have This is that medical Section evaluating account quality I great Hanson, procedures. would important from Gastroenterology of stated acting quote, achieve take canceled our patients EVS. complete just to a allowed travel Pure-Vu feedback to an otherwise have for us or complicated aborted. and often is who
country, evaluating opportunity the for the of across consists Pure-Vu system. US, number a adoption hospitals With system the in the overall approximately growing represents EVS VA high-yield Pure-Vu of we which medical of centers the the VA believe EVS, XXX
discuss let's catalysts. our Now, progress on upcoming key
activity first me clinical Let our study review outpatient strategy. reimbursement and
and the XXXX, recently Our from announced we European that which Disease this line are field to gastrointestinal person XX May expected DDW of world's Digestive results is through clinical top endoscopy meeting and gastroenterology, in hepatology, the place enrolled, the virtually premier surgery. researchers will outpatient take during study and in Week physicians, be XXth. study just for is fully industry the presented and
to system. at with reminder, being using Boston Union in outcomes from limited this The restrictions post poor of improvement with in patients the has low-volume bowel a a the health study procedure, is is baseline of the as XX As conducted history diet European The all is two study primary Scale. prep Pure-Vu the and preparation evaluating The clinical bowel study investigator-initiated patients. assessed Bowel enrolled endpoint preparation the by and centers Preparation for a
to opinion step million health the and million approximately for procedure. critical aborted economic approximately with repeat previously world-class clinical XX clinical study trial. both solicit and reimbursement. EU CMS into input generating large Based for for position through we've from via X.X from care to including lead of burden leaders, have outpatient feedback diligently system procedures each developed to US process and data is high-quality protocol struggle study, these design key currently, the their patient, of outcomes This from the Pure-Vu a economic a discussed, procedures, and in There outpatient the aforementioned the get been clinical year, As recently the a this prior group to we perspective. are puts multipronged and working conducted this in prep which multicenter meeting patients and strategy a a on detailed design. in a their to can on delayed, and A incorporation
to One initiate this keep we'll end study expect before commercial additional relates setting. of to We progress. it XXXX, and into our outpatient the apprised the as of selling Pure-Vu point you
units, outpatient place. previously hospital-based the affairs in medical as progress making reimbursement as in having without well specific are centers mentioned We veteran
new initiated In calls, product a terms platform. of previous I the Pure-Vu on innovation, GI project have capabilities discussed as we've to add EVS upper ongoing to
a to much broad as EVS of optimized will and jets, efficient be key enhancements the suction the flexibility in provide smaller in system, a more procedure. such allow profile to Some channel, the EGD system an improved larger further utility irrigation
we've utility especially were the impair not upper of previously, XXX,XXX only GI As bleeding the but discussed clots cases important can this and stomach in field blood blood content, is view.
collaborations. potential turning to Finally, and strategic partnerships
momentum in built we XXXX could in relationships As strategic adoption our with and become we partners and we've potential ramp, actionable. the that build hospitals believe revenue US to begins
for our to partnerships will opportunities continue turn exploring We our our Andrew? I to Andrew strategy provide the that potential partners call product now XXXX to over that, progress With these our advance commercial of on with financials. value and/or accelerate abreast keep of QX the for aim shareholders. detail and
